ARS Pharmaceuticals Inc [NASDAQ: SPRY] price surged by 4.56 percent to reach at $0.65.
The one-year SPRY stock forecast points to a potential upside of 37.96. The average equity rating for SPRY stock is currently 1.00, trading closer to a bullish pattern in the stock market.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Guru’s Opinion on ARS Pharmaceuticals Inc [SPRY]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SPRY shares is $24.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SPRY stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Cantor Fitzgerald have made an estimate for ARS Pharmaceuticals Inc shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on August 20, 2024. While these analysts kept the previous recommendation, Raymond James raised their target price from $18 to $22. The new note on the price target was released on August 13, 2024, representing the official price target for ARS Pharmaceuticals Inc stock. Previously, the target price had yet another raise from $19 to $20, while Leerink Partners kept a Outperform rating on SPRY stock.
The Average True Range (ATR) for ARS Pharmaceuticals Inc is set at 0.98, with the Price to Sales ratio for SPRY stock in the period of the last 12 months amounting to 2886.87. The Price to Book ratio for the last quarter was 6.71, with the Price to Cash per share for the same quarter was set at 2.26.
SPRY Stock Performance Analysis:
ARS Pharmaceuticals Inc [SPRY] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 14.01. With this latest performance, SPRY shares gained by 38.51% in over the last four-week period, additionally plugging by 98.01% over the last 6 months – not to mention a rise of 122.90% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SPRY stock in for the last two-week period is set at 77.24, with the RSI for the last a single of trading hit 82.32, and the three-weeks RSI is set at 73.60 for ARS Pharmaceuticals Inc [SPRY]. The present Moving Average for the last 50 days of trading for this stock 10.20, while it was recorded at 13.80 for the last single week of trading, and 7.98 for the last 200 days.
Insight into ARS Pharmaceuticals Inc Fundamentals:
ARS Pharmaceuticals Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 32.78 and a Current Ratio set at 32.78.
SPRY Stock EPS
With the latest financial reports released by the company, ARS Pharmaceuticals Inc posted -0.16/share EPS, while the average EPS was predicted by analysts to be reported at -0.18/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.02. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SPRY.
ARS Pharmaceuticals Inc [SPRY] Institutonal Ownership Details
There are presently around $65.20%, or 85.18%% of SPRY stock, in the hands of institutional investors.
